Please use this identifier to cite or link to this item:
|Title:||Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling||Authors:||Ng, S.-B.
|Keywords:||gene expression profiling
|Issue Date:||Mar-2011||Citation:||Ng, S.-B., Selvarajan, V., Huang, G., Zhou, J., Feldman, A.L., Law, M., Kwong, Y.-L., Shimizu, N., Kagami, Y., Aozasa, K., Salto-Tellez, M., Chng, W.-J. (2011-03). Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. Journal of Pathology 223 (4) : 496-510. ScholarBank@NUS Repository. https://doi.org/10.1002/path.2823||Abstract:||We performed comprehensive genome-wide gene expression profiling (GEP) of extranodal nasal-type natural killer/T-cell lymphoma (NKTL) using formalin-fixed, paraffin-embedded tissue (n = 9) and NK cell lines (n = 5) in comparison with normal NK cells, with the objective of understanding the oncogenic pathways involved in the pathogenesis of NKTL and to identify potential therapeutic targets. Pathway and network analysis of genes differentially expressed between NKTL and normal NK cells revealed significant enrichment for cell cycle-related genes and pathways, such as PLK1, CDK1, and Aurora-A. Furthermore, our results demonstrated a pro-proliferative and anti-apoptotic phenotype in NKTL characterized by activation of Myc and nuclear factor kappa B (NF-κB), and deregulation of p53. In corroboration with GEP findings, a significant percentage of NKTLs (n = 33) overexpressed c-Myc (45.4%), p53 (87.9%), and NF-κB p50 (67.7%) on immunohistochemistry using a tissue microarray containing 33 NKTL samples. Notably, overexpression of survivin was observed in 97% of cases. Based on our findings, we propose a model of NKTL pathogenesis where deregulation of p53 together with activation of Myc and NF-κB, possibly driven by EBV LMP-1, results in the cumulative up-regulation of survivin. Down-regulation of survivin with Terameprocol (EM-1421, a survivin inhibitor) results in reduced cell viability and increased apoptosis in tumour cells, suggesting that targeting survivin may be a potential novel therapeutic strategy in NKTL. © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.||Source Title:||Journal of Pathology||URI:||http://scholarbank.nus.edu.sg/handle/10635/109154||ISSN:||00223417||DOI:||10.1002/path.2823|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Mar 1, 2021
WEB OF SCIENCETM
checked on Mar 1, 2021
checked on Feb 27, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.